Hepatitis C disease is caused by hepatitis C virus (HCV) which causes chronic infections in about 180 million individuals worldwide. HCV has been identified as the etiologic agent of hepatitis C in 1989 and for the longest time it is very difficult to treat chronic carriers who are at risk of developing severe liver disease. Now there are three main combined treatments which can increase curative ratio from 10% to more than 90%. The advents of so called directly, acting antivirals (DAAs) in the last few years has revolutionized HCV treatment as these drug combinations can effectively cure HCV in the great majority of patients. The impact of DAAs on global disease burden has been limited, however, by the very drug prices. In this paper the situation was analyzed in China, Europe and Australia. DAAs have been made available to patients in Europe and Australia for several years and are generally accessible. The treatment is highly subsidized by the government, thereby making it possible for all patients in need to access therapy. DAAs have only been very recently been adopted for treatment of chronic hepatitis C in China. In our research, only the method of literature search from both Chinese websites and Foreign websites including journals, magazines and internet search is used. We analyze and compare the solutions that each of these countries is providing to their respective patient populations. Given the large number of chronic HCV carriers in China and other less developed countries solutions have to be found to produce DAAs most cost effectively.
these not specific symptoms, it is still very difficult to distinguish HCV infection from any other acute viral hepatitis [3] (Tyagi et al., 2017) . About 70% -80% acute HCV affection will finally progress to chronicity. Only approximately 20% -30% acute infections can cure spontaneously [4] (Ray, S.C. et al., 2013) . Studies have shown that young women are more likely to resolve the infection [5] (Seeff, 2002) . Chronic HCV infection frequently results in progressive liver disease. 5% -20% of chronic carriers will progress to cirrhosis after approximately 25 years [4] (Stuart et al., 2013 ). The disease also links to fibrosis and hepatocellular carcinoma (HCC) [5] (Seeff, 2004) . After that, the process of some cirrhosis will slow and 10% to 20% will decompensate clinically within 5 years. At this stage, the patient may have some signs indicating chronic liver disease like caput medusae, spider angiomas, palmar erythema, asterixis, anasarca, fluid thrill [3] (Tyagi et al., 2017 ). This slow development of hepatitis C can be accelerated by heavy alcohol intake and co-infection [6] (Hajarizadeh et al., 2013) . Chronic HCV infection is one of the leading causes of death among human immunodeficiency virus (HIV) infected people [7] (Koziel et al., 2007) . HCV can also co-infect with hepatitis B virus (HBV). Furthermore, HIV/HBV co-infection is associated with accelerated fibrosis progression and cirrhosis [3] (Tyagi et al., 2017 ). Special regiments need to be made to treat the co-infection patients.
Hepatitis C Virus
In 1989 Choo and colleagues identified HCV as the etiologic agent of so called non-A non-B hepatitis, which was later renamed as hepatitis C. As HCV is as similar as the structure and function of flaviviruses, it is classified as part of the Flaviviridae family, genus hepacivirus. Based on sequence analysis at least 7 distinct HCV genotypes have been defined, which have different prevalence across the globe [8] [9] (Miao et al., 2017) (Murphy et al., 2016) . In each patient there are numerous genetic variants, referred to quasispecies that are generated during the highly error-prone replication process.
The structure of HCV makes CHC a worldwide disease difficult to treat. Currently, the drug such as DAA can effectively suppress the viral replication which mainly target on the loophole in the structure of HCV. HCV is a small particle with 55 -65 nm in size (see Figure 1 ) (HCV in liver is 80 nm in size, while in blood is 36 -40 nm in size). It is enveloped with glycoprotein, and constituted by a positive single-strand RNA genome as its hereditary material in its core, which surrounded by an icosahedral protected shell of protein-the viral nucleocapsid.
The capids is surrounded by a host derived membrane in which the viral E1 and E2 glycoproteins are incorporated [10] HCV's exclusive replicative reservoir in the human body is the hepatocyte. As viral particles enter human body, LDLR is hydrolysed by LPL and with the help of lipase to transform VLDL to LDL. LVPs then interact with the scavenger receptor class B member1 (SR-BI), due to relatively elevated affinity to exposed E2. Two tight junction proteins, claudin-1 (CLDN1) and occludin (OCLN) are crucial for HCV uptake that is eventually facilitated through receptor mediated endocytosis. The endosome containing viral particles is subsequently acidified leading to conformational changes in the viral envelop proteins which induce fusion of the viral with the endosomal membrane. Thereby, the viral nucleocapids is released into the cytoplasm where it starts to disassemble liberating the viral RNA. For HCV assembly, viral particles are assembled in close association with lipid droplets. Viral particles associate closely with host derived lipoproteins and notably APOE, forming so called lipoviroparticles. AP-2-associated protein kinase 1 (AAK1) and the association with cyclin G-associated kinase (GAK) assembly independently on entering the host cell by controlling AP-2binding to the protein in the core of HCV, which is on lipid droplets (see Figure 2 and Figure 3 ). HCV particles are released along the very low density lipoprotein excretion pathway. IFNs are released as a result of viral infection recognition, inducing actions of a series of enzymes such as protein kinase R (PKR), eIF-2 and RNASE L to inhibit protein synthesis hence destroying the virus and infected host cells. IFNs induce the production of interferon-stimulated genes (ISGs), proteins that combat viruses and participate other interferon actions [13] 
Antiviral Therapies

Direct-Acting Antivirals (DAAs)
Given the relatively low cure rate and unwanted side effects brought by IFN and RBV regimens for hepatitis C, a more effective therapy was needed, which is Other major factors that lead to the infection of HCV in Australia include inappropriate medical procedures and other forms of blood-to-blood contact such as unsterile tattooing [45] (Hepatitis C Virus Infection Consensus Statement Working Group, 2017). Although the hepatitis C problem is severe in Australia, its hepatitis C treatment policy is one of the most progressive and arguably effective in the world, highly accessible and effective.
As a result of the significant prevalence in Australia, Australian government establishes an elaborate series of health care procedures to target at HCV. Since 1990, an acute test for hepatitis C diagnosis has been available, whose principle is 2015) . After taking all these examinations, Australian citizens can then derive prescriptions of DAAs, the most advanced hepatitis C treatment worldwide, from doctors, general practitioners (GPs), or specialists such as gastroenterologists, hepatologists or infectious diseases physicians. After that patients will undergo a course of treatment ranging between 8 and 24 weeks followed by ideal treatments or extra treatments depending on individual's variant need.
Since 1 January 2017, the HCV medicine used in Australia has been DAAs, whose SVR rate is over 90% and mainly including Daklinza 
Europe
HCV also remains highly prevalent in Europe and a variety of treatment options are now becoming available to treat HCV in European countries. In the past 15 years, worldwide efficacy of the therapeutic options for HCV has dramatically improved [49] (European Association for the Study of the Liver, 2012). In Europe, some developed countries such as Britain and Italy adopted treatments that are benefiting the infected people and promoting the process of developing effective drugs. In 1990, globally, just 10% among patients had been treated with interferon monotherapy. The rate has been significantly increased in these days with the help of advanced technology. The cure rate, measured by SVR has been improved up to 80% in some particular GT with current treatment so called standard of care (SOC) and are desired to reach up to 90% or more with employment of DAA [50] (Poordad et al., 2012). Nowadays, for any kind of treatment, the time for therapy will be different. By looking at the response to drugs by virus, patients who rapidly clear virus from their body will be eligible to receive a shorter duration of therapy. On the other hand, patients who has much more severe problems which caused by virus infection will be provided an extended duration of therapy [48] (Lucy, 2017) .
In European countries, there is a large proportion of chronic hepatitis C (CHC) infected people, approximately 1%, who are most age 60 years and older.
Many of these patients have progressed in their disease and are now presenting with severe liver problems. Almost 80,000 are cirrhotic of which at least 3000 suffer from liver decompensation. Moreover, infection due to transplant is about 500 per year and end with death caused by HCV is about 10,000 per year [51] (Vigana et al., 2017). DAAs are now widely used across different European countries and show remarkable treatment successes. In Italy, according to The Italian Medications Agency (AIFA), merely patients with very severe problems with liver can be treated by DAAs. Mostly, patients will take drugs if they have CHC, HCV recurrence after liver transplant of solid organ despite of liver, or liver disease with extra-hepatic manifestations. Furthermore, the price of DAA was still negotiated with price/volume agreement then it is desirable to have the full treatment with nearly 6000 -10,000 Euros.
DAA is expected to be used in treating HCV in long term [52] (Sciences et al.,   2012 ). In the future improvement on DAA, there will be less RBV involved in the combination treatment and the quality and quantity of SVR will be the dominant part in the therapy. Fortunately, DAAs are not only highly effective but also show few sides effects increasing the comfort for patients to follow the therapy. With the help of the new advanced version of therapy, HCV will have the potential to be eradicated from the world [51] (Lucy, 2017) . In Scotland, failed treatment of HCV will not cost the patient the money for drugs. The money will be returned to patient. The manufacture, Janssen, will pay money for pre-treatment of the blood test for patient to predict whether the treatment will be useful or not for patients before they take the therapy.
In 
China
It is estimated that there are approximately 13 million HCV infected persons in Table 1 ). In addition to intravenous drug use (IVDU) with contaminated needles that represent the most dominant way of HCV transmission in developed countries, risk factors in China also include transfusions of contaminated blood products and unsterilized syringe [57] (Duan et al., 2014) Among the infected population, only 25% can be cured while 75% will finally progress to CHC. CHC patients are likely to undergo fibrosis progress, decom- For European countries, the situation is that by looking at its even GDP, it is relatively affordable comparing to that of China. The treatment is meanly PEG + IFN alpha + Simeprevir with or without RBN, depend on the condition of patients. The population of patient is also much smaller than that of China.
2 and 3 can achieve high SVR of 70% -80%, yet patients with GT 1 or 4 achieve 
Comprehensive Analysis
Through studying HCV-treatment conditions in Australia and Europe, a basic knowledge of how they establish DAAs to broader spectrum of their population has been derived. In Australia, the government spent 1 billion buying new medicines for their entire population and made the most effective therapies available to every Australian citizen. In Europe, the costs for the new, very expensive drugs are covered by the insurance thus more accessible to them. Scotland even returns the cost if the drug is not effective and Britain provides alternative treatments for patients. However, all these effective methods for public HCV treatment are not suitable to China. Firstly, it is not practical for Chinese government to buy treatments for the entire population as Australia did, since the total population of China is too large and the infection rate can reach up to 1.8% -3.7%. Secondly, the GDP per capita in China is $7442, indicating that the majority of Chinese population is not affordable to the DAA treatment ($8560).
The wealth gap is also considerably big in China. As a result, it will be impossible for most Chinese patients to buy the new drugs on their own like Europeans do.
Although the Chinese government cannot follow the exactly same path Australia and Europe do, their cases do provide China with referential experience, for instance, the introduction of DAAs into China. hope for future access to the better drug, since they can expect that the government will develop related health insurance or further reduce the cost of the drug.
In addition, Chinese HCV drug development will be facilitated due to the cooperation with transnational company to produce DAAs.
To conclude, DAAs, the new HCV treatment, has not only provided more preferable HCV therapies, improving the cure rate of HCV in China, but also increased citizens' confidence of the treatment and offered new imputes for Chinese HCV drug invention. As for the limitation of the popularization of the new treatment, the Chinese government is currently striving for fixing solutions and the future improvement is what we can look forward to.
Discussion
DAAs Since the most cost part of a drug is patent, the cost of DAAs can be much lower if patent can be circumvented. Some domestic pharmaceutical manufacturers had already produced some drugs which they have independent intellectual property right on, including danoprevir (ASC08), yimitasvir, ravidasvir.
These are also some pharmaceutical companies waiting for the DAAs invented by foreign countries to lose the patent protection. After that, they will have the chance to produce generic DAAs in China. The new DAAs are produced by transnational corporations, so their price might be higher. In a few years, more and more DAAs are expected to come into China market with the development of many domestic pharmaceutical manufacturers. The domestic DAAs will likely be cheaper. As the diagnosis rate improves, the demand of DAAs will increase dramatically, the competition between pharmaceutical manufacturers will be more intense. Under such circumstances, the price of DAAs will be much lower than what it is now.
There are two advantages of China Market. One is cheap labor, another is potential purchasing ability. Some Chinese pharmaceutical companies take use of An effective way for China is to invent their own DAAs but drug developing usually takes 10 -15 years until a product is on the market. This is too late for millions of patients who are suffering from CHC nowadays. For the future development of drugs that can cure CHC, China needs to play a bigger role in drug intervention to keep population away from suffering the pain of HCV.
